Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 1/2013

01-03-2013 | Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Stem Cell Therapy: Promising Treatment in Heart Failure?

Authors: John H. Loughran, Atul R. Chugh, Imtiaz Ismail, Roberto Bolli

Published in: Current Heart Failure Reports | Issue 1/2013

Login to get access

Abstract

Cardiac repair through the use of regenerative medicine has been a considerable research focus over the last decade. Several stem cell types have been investigated over this timeframe as potential candidates to target post-infarction heart failure. The progression of investigation through the rigors of clinical trial design has provided some answers as to the potential clinical utility of this therapy; although there are many questions that remain. This review will concentrate on the clinical trial results of stem cell therapy for cardiac repair since the turn of the century and discuss some of the points that need clarification before this form of therapy can be considered for widespread applicability.
Literature
1.
• Roger VL, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–220. Updated statistics regarding heart failure in the US, outlining the growing burden of this disease process in the US.PubMedCrossRef
2.
Avery CL, et al. The population burden of heart failure attributable to modifiable risk factors: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2012;60(17):1640–6.PubMedCrossRef
3.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–72.PubMedCrossRef
4.
5.
Titler MG, et al. Cost of hospital care for older adults with heart failure: medical, pharmaceutical, and nursing costs. Health Serv Res. 2008;43(2):635–55.PubMedCrossRef
6.
•• Menasche P, et al. Autologous skeletal myoblast transplantation for cardiac insufficiency. First clinical case. Arch Mal Coeur Vaiss. 2001;94(3):180–2. First ever report of stem cell therapy for cardiac repair.PubMed
7.
Menasche P, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41(7):1078–83.PubMedCrossRef
8.
Menasche P, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189–200.PubMedCrossRef
9.
Duckers HJ, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011;6(7):805–12.PubMedCrossRef
10.
•• Strauer BE, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106(15):1913–8. First ever clinical trial of stem cell therapy for cardiac repair.PubMedCrossRef
11.
Assmus B, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009–17.PubMedCrossRef
12.
Wollert KC, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141–8.PubMedCrossRef
13.
Schachinger V, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1210–21.PubMedCrossRef
14.
Lunde K, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199–209.PubMedCrossRef
15.
Meyer GP, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113(10):1287–94.PubMedCrossRef
16.
Traverse JH, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380–9.
17.
Surder D, et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI). Am Heart J. 2010;160(1):58–64.PubMedCrossRef
18.
Traverse JH, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–9.PubMedCrossRef
19.
• Abdel-Latif A, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007;167(10):989–97. First meta-analysis to describe overall benefit of BMC in the setting of acute MI.PubMedCrossRef
20.
Strauer BE, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol. 2005;46(9):1651–8.PubMedCrossRef
21.
Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12(7):721–9.PubMedCrossRef
22.
Assmus B, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355(12):1222–32.PubMedCrossRef
23.
Perin EC, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717–26.PubMedCrossRef
24.
Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.PubMedCrossRef
25.
Heng TS, et al. Stem cells–meet immunity. J Mol Med (Berl). 2009;87(11):1061–9.CrossRef
26.
El-Badri NS, Maheshwari A, Sanberg PR. Mesenchymal stem cells in autoimmune disease. Stem Cells Dev. 2004;13(5):463–72.PubMedCrossRef
27.
Chen SL, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94(1):92–5.PubMedCrossRef
28.
Florenzano F, Minguell JJ. Autologous mesenchymal stem cell transplantation after acute myocardial infarction. Am J Cardiol. 2005;95(3):435.PubMedCrossRef
29.
Katritsis DG, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv. 2005;65(3):321–9.PubMedCrossRef
30.
Chen S, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18(11):552–6.PubMed
31.
Lo R, Hsia HH. Ventricular arrhythmias in heart failure patients. Cardiol Clin. 2008;26(3):381–403. vi.PubMedCrossRef
32.
Katritsis DG, et al. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace. 2007;9(3):167–71.PubMedCrossRef
33.
Hare JM, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79.
34.
Trachtenberg B, et al. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011;161(3):487–93.PubMedCrossRef
35.
Bartunek J, et al. C-Cure multicenter triall: lineage specified bone marrow derived cardiopoietic mesenchymal stem cells for treatment of ischemic cardiomyopathy. J Am Coll Cardiol. 2011;57:E200.CrossRef
36.
Beltrami AP, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344(23):1750–7.PubMedCrossRef
37.
38.
39.
•• Beltrami AP, Beltrami AP, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763–76. First report of the discovery of endogenous stem cells recovered from the mammalian heart.PubMedCrossRef
40.
Messina E, et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911–21.PubMedCrossRef
41.
•• Bolli R, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–57. First in-human clinical trial of CSC for the treatment of post-infarction left ventricular dysfunction.PubMedCrossRef
42.
Chugh AR, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation. 2012;126(11 Suppl 1):S54–64.PubMedCrossRef
43.
•• Makkar RR, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895–904. First clinical trial investigating the use of CDC for the treatment of ischemic heart disease.PubMedCrossRef
44.
Cheng K, et al. Magnetic enhancement of cell retention, engraftment and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia/reperfusion. Cell Transplant. 2012;21(6):1121–35.
45.
Terrovitis J, et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol. 2009;54(17):1619–26.PubMedCrossRef
46.
Freyman T, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006;27(9):1114–22.PubMedCrossRef
47.
Frangogiannis NG. The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. J Am Coll Cardiol. 2011;58(23):2424–6.PubMedCrossRef
48.
Martin-Rendon E, et al. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur Heart J. 2008;29(15):1807–18.PubMedCrossRef
49.
Kutschka I, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation. 2006;114(1 Suppl):I167–73.PubMed
50.
Memon IA, et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg. 2005;130(5):1333–41.PubMedCrossRef
51.
Christman KL, et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44(3):654–60.PubMedCrossRef
52.
Suzuki K, et al. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation. 2000;102(19 Suppl 3):III216–21.PubMed
53.
Laflamme MA, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005;167(3):663–71.PubMedCrossRef
54.
Niagara MI, et al. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007;100(4):545–55.PubMedCrossRef
55.
Pasha Z, et al. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res. 2008;77(1):134–42.PubMedCrossRef
56.
Pons J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun. 2008;376(2):419–22.PubMedCrossRef
57.
Barbash IM, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863–8.PubMedCrossRef
58.
Gupta R, Losordo DW. Challenges in the translation of cardiovascular cell therapy. J Nucl Med. 2010;51 Suppl 1:122S–7.PubMedCrossRef
59.
Flett AS, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2):150–6.PubMedCrossRef
60.
Hung J, et al. Cardiac image modeling tool for quantitative analysis of global and regional cardiac wall motion. Invest Radiol. 2009;44(5):271–8.PubMedCrossRef
61.
Hulten EA, et al. Stress CT perfusion: coupling coronary anatomy with physiology. J Nucl Cardiol. 2012;19(3):588–600.PubMedCrossRef
62.
Morton G, et al. Quantitative cardiovascular magnetic resonance perfusion imaging: inter-study reproducibility. Eur Heart J Cardiovasc Imaging. 2012;13(11):954–60.PubMedCrossRef
63.
Haas F, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30(7):1693–700.PubMedCrossRef
64.
Baer FM, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation. 1995;91(4):1006–15.PubMedCrossRef
65.
Tillisch J, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884–8.PubMedCrossRef
Metadata
Title
Stem Cell Therapy: Promising Treatment in Heart Failure?
Authors
John H. Loughran
Atul R. Chugh
Imtiaz Ismail
Roberto Bolli
Publication date
01-03-2013
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 1/2013
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-012-0128-2

Other articles of this Issue 1/2013

Current Heart Failure Reports 1/2013 Go to the issue

Pharmacologic Therapy (WHW Tang, Section Editor)

Mineralocorticoid Receptor Antagonism Confers Cardioprotection in Heart Failure

Pharmacologic Therapy (WHW Tang, Section Editor)

Novel Therapeutic Approaches to Preserve the Right Ventricle

Pharmacologic Therapy (WHW Tang, Section Editor)

Micronutrients in Chronic Heart Failure

Pharmacologic Therapy (WHW Tang, Section Editor)

Novel Vasodilators in Heart Failure

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Genetic Testing in the Contemporary Diagnosis of Cardiomyopathy

Pharmacologic Therapy (WHW Tang, Section Editor)

Pharmacologic Management of Chronic Reno-Cardiac Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits